Antibacterial agent 325 

Antibacterial agent 325 is an antibacterial agent. Antibacterial agent 325 exerts potent broad-spectrum antibacterial activity and shows bactericidal activity. Antibacterial agent induces membrane depolarization, disrupts the membrane integrity, increasess ROS production and lipid peroxidation levels. Antibacterial agent 325 inhibits the metabolic activity and Lactate Dehydrogenase (LDH) activity. Antibacterial agent 325 exhibits low drug resistance development in bacteria, low hemolysis and cytotoxicity. Antibacterial agent 325 can be used for the research of bacterial infection^[1].

Antibacterial agent 325 (Compound 14a) (0.25-16 μg/mL) exerts potent broad-spectrum in vitro antibacterial activity, with particularly strong efficacy against methicillin-resistant Staphylococcus aureus (MIC = 0.25 μg/mL), Escherichia coli (MIC = 0.25 μg/mL), Klebsiella pneumonia (MIC = 0.5 μg/mL), and Acinetobacter
baumannii (MIC = 0.5 μg/mL)^[1].
Antibacterial agent 325 (0.5-128 μg/mL) exhibits very low hemolytic activity against human red blood cells, with hemolysis rates below 3% across tested concentrations up to 128 μg/mL^[1].
Antibacterial agent 325 (10-100 μg/mL; 24 h) shows low cytotoxicity towards LO2 human hepatocytes^[1].
Antibacterial agent 325 exhibits synergistic in vitro antibacterial activity with Norfloxacin (HY-B0132) against both E. coli and MRSA, with an FICI of 0.25 for both strains^[1].
Antibacterial agent 325 (0.25-1 μg/mL; 12 h) demonstrates rapid bactericidal activity against MRSA, with complete eradication of the strain within 12 h at 4× MIC^[1].
Antibacterial agent 325 (16 days) has a low potential to induce MRSA resistance, with no increase in MIC observed over 16 serial passages^[1].
Antibacterial agent 325 (0.25-1 μg/mL; 10-30 min) induces significant, time-dependent membrane depolarization in MRSA^[1].
Antibacterial agent 325 (0.25-1.5 μg/mL) disrupts the membrane integrity of MRSA in a dose-dependent manner, as shown by increased PI uptake and reduced calcein-AM retention^[1].
Antibacterial agent 325 (0.25-2 μg/mL) causes dose-dependent protein leakage from MRSA^[1].
Antibacterial agent 325 (0.25-2.5 μg/mL; 30-150 min) induces dose-dependent and time-dependent ROS production in MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) induces dose-dependent lipid peroxidation in MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) impairs the antioxidant defense system of MRSA cells, causing a dose-dependent loss of GSH activity^[1].
Antibacterial agent 325 (2 μg/mL; 6 h) causes visible morphological damage and shrinkage of MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) dose-dependently inhibits the metabolic activity of MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) dose-dependently inhibits MRSA LDH activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Antibacterial agent 325 (Compound 14a) (0.100 mg/kg; topical administration; every 48 h; 2 dose) inhibits the inflammatory effect
caused by bacterial infection and promote wound healing in mouse wound MRSA-infected models^[1].
Antibacterial agent 325 (0.067-0.1 mg/kg) increases the survival rate of the Galleria mellonella larvae with MRSA infection^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

469.94

C₂₅H₂₅ClFN₃O₃

O=C1C2=CC(F)=C(/C(C#N)=C/C3=C(Cl)C=C(CCCC)N3CC)C=C2N(CC)C=C1C(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tan YM, et al. Discovery of novel structural imidazolylvinylquinolones exerting excellent broad-spectrum antibacterial efficacy with multitargeting potential. Eur J Med Chem. 2026;307:118643.  [Content Brief]